-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-01
IQV:NYE- (USD)
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 171.24Change
-5.06 (-2.87)%Market Cap
USD 33.79BVolume
1.23MVerdict
Verdict
Values as of: 2025-04-01
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 171.24Change
-5.06 (-2.87)%Market Cap
USD 33.79BVolume
1.23MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
DHR | Danaher Corporation |
+4.77 (+2.38%) |
USD 151.57B |
A | Agilent Technologies Inc |
+1.94 (+1.70%) |
USD 36.12B |
LH | Laboratory Corporation of Amer.. |
+3.72 (+1.60%) |
USD 21.18B |
DGX | Quest Diagnostics Incorporated |
-1.32 (-0.78%) |
USD 18.88B |
CRL | Charles River Laboratories |
+3.29 (+2.25%) |
USD 9.00B |
QGEN | Qiagen NV |
+0.52 (+1.32%) |
USD 8.30B |
ENZ | Enzo Biochem Inc |
-0.01 (-2.21%) |
USD 0.03B |
TMO | Thermo Fisher Scientific Inc |
+6.09 (+1.26%) |
N/A |
WAT | Waters Corporation |
+6.64 (+1.87%) |
N/A |
MTD | Mettler-Toledo International I.. |
+16.12 (+1.39%) |
N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
EKG | First Trust Nasdaq Lux Di.. | 6.09 % | 0.00 % |
+0.19 (+1.22%) |
USD 2.40M |
BBH | VanEck Biotech ETF | 4.25 % | 0.35 % |
+1.81 (+1.22%) |
USD 0.40B |
IBB | iShares Biotechnology ETF | 3.33 % | 0.47 % |
+2.35 (+1.22%) |
USD 6.00B |
GNRX | 0.00 % | 0.55 % |
N/A |
N/A | |
PBI | Pitney Bowes Inc | 0.00 % | 0.79 % |
+0.11 (+1.22%) |
USD 1.74B |
HIG:CA | Global Healthcare Income .. | 0.00 % | 1.02 % |
N/A |
CAD 0.05B |
XSD2:LSE | db x-trackers ShortDAX x2.. | 0.00 % | 0.00 % |
+0.84 (+1.22%) |
USD 0.10B |
DBPD:XETRA | Xtrackers ShortDAX x2 Dai.. | 0.00 % | 0.00 % |
+0.01 (+1.22%) |
USD 0.13B |
VNMC | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Diagnostics & Research) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -12.86% | 42% | F | 15% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -12.86% | 33% | F | 15% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -30.25% | 25% | F | 10% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -30.25% | 25% | F | 9% | A- | ||
Trailing 5 Years | |||||||
Capital Gain | 63.43% | 45% | F | 54% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 63.43% | 45% | F | 43% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 11.09% | 75% | C | 69% | C- | ||
Dividend Return | 11.09% | 67% | D+ | 63% | D | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 28.83% | 42% | F | 35% | F | ||
Risk Adjusted Return | 38.45% | 67% | D+ | 53% | F | ||
Market Capitalization | 33.79B | 75% | C | 94% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.